Inovio Pharmaceuticals (NSDQ:INO) touted today positive safety and immune response data from the first-in-man Phase I trial of its vaccine against the Zika virus.
The trial showed that Inovio’s DNA-based vaccine triggered high levels of binding antibodies in all 40 participants. The team also reported observing a strong neutralizing antibody and T-cell immune response in vaccinated participants.
Get the full story at our sister site, Drug Delivery Business News.
The post Inovio touts first-in-man Ph1 trial of Zika virus vaccine appeared first on MassDevice.
from MassDevice http://ift.tt/2kpRJZF
Cap comentari:
Publica un comentari a l'entrada